☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
overall VE of 61.2% against VCD with 64.2% & 53.5% VE in seropositive & negative patients. The results were consistent with prior reported results
Takeda Presents Results of TAK-003 in P-III (TIDES) Trial for the Prevention of Dengue at NECTM8 2022
June 9, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.